UnityPoint Health - Des Moines

Hematologic Cancer Research Studies

Multiple Myeloma

E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, LENalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

MDS

NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study